Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.84 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12185581 | 0.91 | PRCP (1.00) | PRCPTLR9TLR8TLR7SLC18A3 | |
| SCHEMBL14701354 | 0.91 | PRCP (0.84) | PRCPTLR9TLR8TLR7SLC18A3 | |
| SCHEMBL14701327 | 0.88 | PRCP (0.84) | PRCPADRA1DADRA1AADRA1B | |
| SCHEMBL14701324 | 0.88 | PRCP (0.66) | PRCPTLR9TLR8TLR7ADRA1D | |
| SCHEMBL14701325 | 0.86 | PRCP (0.86) | PRCPMEN1KMT2AADRA1DADRA1A | |
| SCHEMBL14701326 | 0.82 | PRCP (0.83) | PRCPMEN1KMT2A | |
| SCHEMBL12185600 | 0.81 | PRCP (0.70) | PRCPTLR9TLR8TLR7SLC18A3 | |
| SCHEMBL12185983 | 0.80 | PRCP (0.85) | PRCP | |
| SCHEMBL12185582 | 0.79 | PRCP (1.00) | PRCP | |
| SCHEMBL12185577 | 0.79 | PRCP (0.86) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885TLR9 4820/4885TLR8 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.